This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Menu
Book
DAY TWO WATCH LIVE (EST); 20/10/20keyboard_arrow_right

DAY TWO WATCH LIVE (EST); 20/10/20

search

DAY TWO WATCH LIVE (EST); 20/10/20

search
This agenda is just the start. Wherever you are in the world, the Cell Therapy Bioprocessing & Commercialization and Cell Therapy Manufacturing & Gene Therapy Congresses are coming to you. The talks listed here are just the tip of the iceberg. Please also make sure to browse all of our 'on-demand' sessions which available to watch at your convenience.
8:00am - 8:30am30 mins
Cell Therapy
Lets get moving PT session
    8:00am - 8:30am30 mins
    Gene Edited Ex Vivo Cell Therapy
    Lets get moving PT session
      8:00am - 8:30am30 mins
      In Vivo Gene Therapy
      Lets get moving PT session
        8:00am - 8:30am30 mins
        Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
        Lets get moving PT session
          8:30am - 9:00am30 mins
          Cell Therapy
          Exhibtion Viewing Time & Networking Breakfast
            8:30am - 9:00am30 mins
            Gene Edited Ex Vivo Cell Therapy
            Exhibtion Viewing Time & Networking Breakfast
              8:30am - 9:00am30 mins
              In Vivo Gene Therapy
              Exhibtion Viewing Time & Networking Breakfast
                8:30am - 9:00am30 mins
                Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
                Exhibtion Viewing Time & Networking Breakfast
                  9:00am - 9:10am10 mins
                  Cell Therapy
                  Chairperson’s Opening Remarks
                  • David Smith - President and Chief Commercial Officer, Akron Biotech, USA
                  9:00am - 9:10am10 mins
                  Gene Edited Ex Vivo Cell Therapy
                  Chairperson’s Opening Remarks
                  • David Smith - President and Chief Commercial Officer, Akron Biotech, USA
                  9:00am - 9:10am10 mins
                  In Vivo Gene Therapy
                  Chairperson’s Opening Remarks
                  • David Smith - President and Chief Commercial Officer, Akron Biotech, USA
                  9:00am - 9:10am10 mins
                  Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
                  Chairperson’s Opening Remarks
                  • David Smith - President and Chief Commercial Officer, Akron Biotech, USA
                  9:10am - 9:30am20 mins
                  Cell Therapy
                  Fate Therapeutic’s Off-the-shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy Programs
                  • Betsy Rezner - Director, Process & Assay Development, Fate Therapeutics Inc.
                  9:10am - 9:30am20 mins
                  Gene Edited Ex Vivo Cell Therapy
                  Fate Therapeutic’s Off-the-shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy Programs
                  • Betsy Rezner - Director, Process & Assay Development, Fate Therapeutics Inc.
                  9:10am - 9:30am20 mins
                  In Vivo Gene Therapy
                  Fate Therapeutic’s Off-the-shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy Programs
                  • Betsy Rezner - Director, Process & Assay Development, Fate Therapeutics Inc.
                  9:10am - 9:30am20 mins
                  Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
                  Fate Therapeutic’s Off-the-shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy Programs
                  • Betsy Rezner - Director, Process & Assay Development, Fate Therapeutics Inc.
                  9:30am - 9:50am20 mins
                  Cell Therapy
                  Scalable Manufacture Platform of Human iPS-NK Cells for Off-the-Shelf Cell Therapies
                  • Allen Feng - Chief Scientific Officer, HebeCell Corp., USA
                  9:30am - 9:50am20 mins
                  Gene Edited Ex Vivo Cell Therapy
                  Scalable Manufacture Platform of Human iPS-NK Cells for Off-the-Shelf Cell Therapies
                  • Allen Feng - Chief Scientific Officer, HebeCell Corp., USA
                  9:30am - 9:50am20 mins
                  In Vivo Gene Therapy
                  Scalable Manufacture Platform of Human iPS-NK Cells for Off-the-Shelf Cell Therapies
                  • Allen Feng - Chief Scientific Officer, HebeCell Corp., USA
                  9:30am - 9:50am20 mins
                  Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
                  Scalable Manufacture Platform of Human iPS-NK Cells for Off-the-Shelf Cell Therapies
                  • Allen Feng - Chief Scientific Officer, HebeCell Corp., USA
                  9:50am - 10:10am20 mins
                  Cell Therapy
                  Non-Gene Edited Approaches to Allogeneic CAR-T Cell Therapy
                  • Philippe Parone - Director, Industrialization, Celyad, Belgium
                  9:50am - 10:10am20 mins
                  Gene Edited Ex Vivo Cell Therapy
                  Non-Gene Edited Approaches to Allogeneic CAR-T Cell Therapy
                  • Philippe Parone - Director, Industrialization, Celyad, Belgium
                  9:50am - 10:10am20 mins
                  In Vivo Gene Therapy
                  Non-Gene Edited Approaches to Allogeneic CAR-T Cell Therapy
                  • Philippe Parone - Director, Industrialization, Celyad, Belgium
                  9:50am - 10:10am20 mins
                  Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
                  Non-Gene Edited Approaches to Allogeneic CAR-T Cell Therapy
                  • Philippe Parone - Director, Industrialization, Celyad, Belgium
                  10:10am - 10:30am20 mins
                  Cell Therapy
                  The Potential CAR-NK
                  • Kathryn Corzo - Head of Development Oncology Cell Therapies, Takeda
                  10:10am - 10:30am20 mins
                  Gene Edited Ex Vivo Cell Therapy
                  The Potential CAR-NK
                  • Kathryn Corzo - Head of Development Oncology Cell Therapies, Takeda
                  10:10am - 10:30am20 mins
                  In Vivo Gene Therapy
                  The Potential CAR-NK
                  • Kathryn Corzo - Head of Development Oncology Cell Therapies, Takeda
                  10:10am - 10:30am20 mins
                  Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
                  The Potential CAR-NK
                  • Kathryn Corzo - Head of Development Oncology Cell Therapies, Takeda
                  10:30am - 11:00am30 mins
                  Cell Therapy
                  Data driven strategies for downstream processing of Plasmid DNA in viral vector production
                  • Thomas Parker - Process Development Scientist, Global Focal Point for Vaccines and Viral Therapies, MilliporeSigma
                  10:30am - 11:00am30 mins
                  Gene Edited Ex Vivo Cell Therapy
                  Data driven strategies for downstream processing of Plasmid DNA in viral vector production
                  • Thomas Parker - Process Development Scientist, Global Focal Point for Vaccines and Viral Therapies, MilliporeSigma
                  10:30am - 11:00am30 mins
                  In Vivo Gene Therapy
                  Data driven strategies for downstream processing of Plasmid DNA in viral vector production
                  • Thomas Parker - Process Development Scientist, Global Focal Point for Vaccines and Viral Therapies, MilliporeSigma
                  10:30am - 11:00am30 mins
                  Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
                  Data driven strategies for downstream processing of Plasmid DNA in viral vector production
                  • Thomas Parker - Process Development Scientist, Global Focal Point for Vaccines and Viral Therapies, MilliporeSigma
                  11:00am - 11:20am20 mins
                  Cell Therapy
                  Starting Material Standardization
                  • Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
                  11:00am - 11:20am20 mins
                  Gene Edited Ex Vivo Cell Therapy
                  Starting Material Standardization
                  • Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
                  11:00am - 11:20am20 mins
                  In Vivo Gene Therapy
                  Starting Material Standardization
                  • Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
                  11:00am - 11:20am20 mins
                  Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
                  Scaffold Fabrication
                  • Michael Francis - Chief Scientific Officer - Co-Founder, Embody, Faculty at EVMS
                  11:20am - 11:45am25 mins
                  Cell Therapy
                  Speaker Q&A - Raw Material, Viral Vector & Supply Chain Considerations
                  • Christopher Bravery - Director, Consulting on Advanced Biologicals Ltd., Member, ISCT EU Legal and Regulatory Affairs Committee, UK
                  • Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
                  • Scott Burger - Principal, Advanced Cell & Gene Therapy, USA
                  • Tom Walls - Global Planning and Logistics Lead, Spark Therapeutics, USA
                  • Max Sellman - Product Manager, Gene Editing, Aldevron, USA
                  • Sylvain Cecchini - Associate Professor of Microbiology & Physiological Systems, University of Massachusetts Medical School, USA
                  11:20am - 11:45am25 mins
                  Gene Edited Ex Vivo Cell Therapy
                  Speaker Q&A - Raw Material, Viral Vector & Supply Chain Considerations
                  • Christopher Bravery - Director, Consulting on Advanced Biologicals Ltd., Member, ISCT EU Legal and Regulatory Affairs Committee, UK
                  • Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
                  • Scott Burger - Principal, Advanced Cell & Gene Therapy, USA
                  • Tom Walls - Global Planning and Logistics Lead, Spark Therapeutics, USA
                  • Max Sellman - Product Manager, Gene Editing, Aldevron, USA
                  • Sylvain Cecchini - Associate Professor of Microbiology & Physiological Systems, University of Massachusetts Medical School, USA
                  11:20am - 11:45am25 mins
                  In Vivo Gene Therapy
                  Speaker Q&A - Raw Material, Viral Vector & Supply Chain Considerations
                  • Christopher Bravery - Director, Consulting on Advanced Biologicals Ltd., Member, ISCT EU Legal and Regulatory Affairs Committee, UK
                  • Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
                  • Scott Burger - Principal, Advanced Cell & Gene Therapy, USA
                  • Tom Walls - Global Planning and Logistics Lead, Spark Therapeutics, USA
                  • Max Sellman - Product Manager, Gene Editing, Aldevron, USA
                  • Sylvain Cecchini - Associate Professor of Microbiology & Physiological Systems, University of Massachusetts Medical School, USA
                  11:20am - 11:45am25 mins
                  Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
                  Speaker Q&A
                  • Mary Clare McCorry - Director, Technology and Process Development, Advanced Regenerative Manufacturing Institute (ARMI)
                  • Michael Francis - Chief Scientific Officer - Co-Founder, Embody, Faculty at EVMS
                  • Benjamin Fryer - Founder, Pluristyx, Incorporated, USA
                  • Sonia Bulsara - Application Specialist Manager, US & Canada, Cell and Gene Therapy, Cytiva, USA
                  • Jan Jensen - CEO and Founder, Trailhead Biosystems Inc.
                  11:45am - 12:30pm45 mins
                  Cell Therapy
                  Networking & Additional Content Viewing Time
                    11:45am - 12:30pm45 mins
                    Gene Edited Ex Vivo Cell Therapy
                    Networking & Additional Content Viewing Time
                      11:45am - 12:30pm45 mins
                      In Vivo Gene Therapy
                      Networking & Additional Content Viewing Time
                        11:45am - 12:30pm45 mins
                        Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
                        Networking & Additional Content Viewing Time
                          DAY ONE WATCH LIVE (EST); 19/10/20
                          NextDAY THREE WATCH LIVE (EST); 21/10/20

                          Get the latest news.
                          As it happens

                          Sign up to get the latest on the agenda and speakers.
                          Choose Day